164 related articles for article (PubMed ID: 36211409)
1. Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.
Xie W; Zeng Y; Hu L; Hao J; Chen Y; Yun X; Lin Q; Li H
Front Immunol; 2022; 13():991656. PubMed ID: 36211409
[TBL] [Abstract][Full Text] [Related]
2. Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.
Xia Y; Jiang X; Huang Y; Liu Q; Huang Y; Zhang B; Mei Z; Xu D; Shi Y; Tu W
Front Endocrinol (Lausanne); 2022; 13():895428. PubMed ID: 35757399
[TBL] [Abstract][Full Text] [Related]
3. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
4. The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer.
Xia M; Wang S; Wang L; Mei Y; Tu Y; Gao L
Front Endocrinol (Lausanne); 2023; 14():1062317. PubMed ID: 37025405
[TBL] [Abstract][Full Text] [Related]
5. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
6. Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.
Jin T; Ge L; Chen J; Wang W; Zhang L; Ge M
PeerJ; 2023; 11():e15592. PubMed ID: 37361050
[TBL] [Abstract][Full Text] [Related]
7. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer.
Wen S; Luo Y; Wu W; Zhang T; Yang Y; Ji Q; Wu Y; Shi R; Ma B; Xu M; Qu N
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1579-1589. PubMed ID: 34693452
[TBL] [Abstract][Full Text] [Related]
8. Golgi-apparatus genes related signature for predicting the progression-free interval of patients with papillary thyroid carcinoma.
Liu R; Cao Z; Wu M; Li X; Fan P; Liu Z
BMC Med Genomics; 2023 Mar; 16(1):60. PubMed ID: 36973751
[TBL] [Abstract][Full Text] [Related]
9. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
[TBL] [Abstract][Full Text] [Related]
11. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma.
Wang L; Yao B; Yang J; Tian Z; He J
BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684
[TBL] [Abstract][Full Text] [Related]
12. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
14. A prognostic nomogram for papillary thyroid cancer lymph node metastasis based on immune score.
Lu Y; Qian K; Fei M; Guo K; Shi Y; Wang Z
Front Endocrinol (Lausanne); 2022; 13():993856. PubMed ID: 36531470
[TBL] [Abstract][Full Text] [Related]
15. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors.
Pani F; Yasuda Y; Rousseau ST; Bermea KC; Roshanmehr S; Wang R; Yegnasubramanian S; Caturegli P; Adamo L
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521928
[TBL] [Abstract][Full Text] [Related]
16. Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.
Zhai T; Muhanhali D; Jia X; Wu Z; Cai Z; Ling Y
Endocrine; 2019 Dec; 66(3):573-584. PubMed ID: 31332712
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the prognostic significance and potential mechanisms of lncRNAs associated with m6A methylation in papillary thyroid carcinoma.
Huang Y; Li X; Chen W; He Y; Wu S; Li X; Hou B; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt B):108286. PubMed ID: 34735975
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
[TBL] [Abstract][Full Text] [Related]
19. Spatial transcriptomics reveals prognosis-associated cellular heterogeneity in the papillary thyroid carcinoma microenvironment.
Yan K; Liu QZ; Huang RR; Jiang YH; Bian ZH; Li SJ; Li L; Shen F; Tsuneyama K; Zhang QL; Lian ZX; Guan H; Xu B
Clin Transl Med; 2024 Mar; 14(3):e1594. PubMed ID: 38426403
[TBL] [Abstract][Full Text] [Related]
20. TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer.
Zhao YX; Ma LB; Yang Z; Zhang TH; Wang Y; Xiang C
Biochem Genet; 2024 Apr; 62(2):718-740. PubMed ID: 37410307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
